XNCR Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 68.03
- PEG ratio
- 0.00
- P/B
- 2.51
- P/S (TTM)
- 13.30
- EV/EBITDA
- -17.27
Profitability & growth
- ROE (TTM)
- -29.8%
- Operating margin
- -1724.0%
- Revenue growth YoY
- -86.2%
- Dividend yield
- —
- Beta
- 0.86
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Xencor Inc
Company profileXencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 465 NORTH HALSTEAD STREET, PASADENA, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
